2 citations
,
March 2005 in “Cancer biology & therapy” This study found that 95% of untreated advanced-stage follicular lymphoma patients responded to a single course of the Bexxar regimen, with 75% achieving complete remission and remaining disease-free for years.
September 2023 in “Journal of the American Academy of Dermatology” This study found that in participants with notalgia paresthetica, 8 weeks of treatment with difelikefalin significantly improved itch intensity and increased the rate of strict complete response compared to placebo, starting as early as week 3.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” In this study, researchers described ONCO-NK-TRANSITION-GM1, a cancer therapy that's manufacturable with current pharmaceutical methods, showing a 60-80% complete response rate across various cancer types and costing $50 per dose, providing a more accessible alternative to existing treatments.
2 citations
,
November 2023 in “Acta dermato-venereologica” This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” In this retrospective study of patients with advanced Merkel cell carcinoma responding to immunotherapy, those treated for 18 months or longer showed better progression-free outcomes compared to shorter treatment durations, indicating potential benefits of extended therapy duration.
